Literature DB >> 7536096

The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha.

R Schulz1, D L Panas, R Catena, S Moncada, P M Olley, G D Lopaschuk.   

Abstract

1. Myocardial dysfunction during septic shock is associated with enhanced production of cytokines such as interleukin-1 beta (IL-1 beta) and tumour necrosis factor-alpha (TNF-alpha). These cytokines depress cardiac mechanical function by a mechanism which is not well defined. 2. Bacterial endotoxin or cytokines cause the expression of Ca(2+)-independent nitric oxide (NO) synthase in cardiac myocytes, vascular endothelial cells and endocardial endothelial cells, causing enhanced production of NO. As NO has negative inotropic actions on cardiac muscle, we tested the sum effects of IL-1 beta plus TNF-alpha in the intact heart to determine whether enhanced expression of NO synthase activity in the cells that comprise the heart is involved in cardiac depression associated with cytokine stimulation. 3. Rat isolated working hearts perfused with IL-1 beta plus TNF-alpha showed a markedly greater depression in contractile function, measured as cardiac work, after 2 h of perfusion compared with time-matched control hearts. The depressant action of IL-1 beta plus TNF-alpha was first apparent after 1 h of perfusion; no early (15 min) cardiac depressant actions were seen. 4. The competitive inhibitor of Ca(2+)-dependent and Ca(2+)-independent NO synthases, NG-nitro-L-arginine methyl ester (L-NAME, 3 microM) when given concurrently with IL-1 beta plus TNF-alpha prevented the loss in contractile function such that these hearts after 2 h of perfusion had similar function to time-matched controls. L-NAME did not acutely reverse the loss of contractile function in hearts exposed for 2 h to IL-1 beta plus TNF-alpha. The protective action of L-NAME in the presence of cytokines was concentration-dependent and was not seen at a higher concentration (10 micro M) due to the significant reduction in coronary flow observed at this concentration.5. In contrast, when L-NAME (3 micro M) was given in the absence of IL-l beta plus TNF-alpha it depressed contractile function over the 2 h perfusion period by significantly reducing coronary flow.6. Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7. Inducible, Ca2+-independent NO synthase activity was not observed in freshly isolated hearts but was observed in control hearts perfused for 2 h in vitro and was doubled in hearts perfused with IL-1 beta plus TNF-a. Cx prevented the expression of Ca2+-independent NO synthase in both control and cytokine-treated hearts.8. In summary, these results suggest that the depression of myocardial function by IL-l beta plus TNF-alpha is mediated, at least in part, by induction of Ca2+-independent NO synthase activity in the heart.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536096      PMCID: PMC1510184          DOI: 10.1111/j.1476-5381.1995.tb14901.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

Review 1.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome.

Authors:  C A Dinarello
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Factors released from endocardium of the ferret and pig modulate myocardial contraction.

Authors:  J A Smith; A M Shah; M J Lewis
Journal:  J Physiol       Date:  1991-08       Impact factor: 5.182

Review 3.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

4.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock.

Authors:  A Petros; D Bennett; P Vallance
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

5.  Nitric oxide synthase in cultured endocardial cells of the pig.

Authors:  R Schulz; J A Smith; M J Lewis; S Moncada
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

6.  Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?

Authors:  E Nava; R M Palmer; S Moncada
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

Review 7.  Role of NO in vascular smooth muscle and cardiac muscle function.

Authors:  R Schulz; C R Triggle
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

8.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

9.  Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy.

Authors:  J B Hibbs; C Westenfelder; R Taintor; Z Vavrin; C Kablitz; R L Baranowski; J H Ward; R L Menlove; M P McMurry; J P Kushner
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

10.  Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblotting study.

Authors:  E Arbustini; M Grasso; M Diegoli; M Bramerio; A S Foglieni; M Albertario; L Martinelli; A Gavazzi; C Goggi; C Campana
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

View more
  42 in total

1.  Minocycline reverses IL-17A/TRAF3IP2-mediated p38 MAPK/NF-κB/iNOS/NO-dependent cardiomyocyte contractile depression and death.

Authors:  Tadashi Yoshida; Nitin A Das; Andrea J Carpenter; Reza Izadpanah; Senthil A Kumar; Sandeep Gautam; Shawn B Bender; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2020-06-15       Impact factor: 4.315

2.  Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Authors:  Mohammad A M Ali; Woo Jung Cho; Bryan Hudson; Zamaneh Kassiri; Henk Granzier; Richard Schulz
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

3.  Co-induction of nitric oxide and tetrahydrobiopterin synthesis in the myocardium in vivo.

Authors:  Y Hattori; S Hattori; S Motohashi; K Kasai; S I Shimoda; N Nakanishi
Journal:  Mol Cell Biochem       Date:  1997-01       Impact factor: 3.396

Review 4.  Myocardial infarction and nitric oxide.

Authors:  R J Bing; H Suzuki
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

5.  Alterations in inotropy, nitric oxide and cyclic GMP synthesis, protein phosphorylation and ADP-ribosylation in the endotoxin-treated rat myocardium and cardiomyocytes.

Authors:  P V Sulakhe; L Sandirasegarane; J P Davis; X T Vo; W J Costain; R R Mainra
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

6.  Interleukin-1β reduces L-type Ca2+ current through protein kinase Cϵ activation in mouse heart.

Authors:  Nabil El Khoury; Sophie Mathieu; Céline Fiset
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

7.  Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

8.  Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 9.  Targeting interleukin-1 in heart failure and inflammatory heart disease.

Authors:  Benjamin W Van Tassell; Juan M Valle Raleigh; Antonio Abbate
Journal:  Curr Heart Fail Rep       Date:  2015-02

10.  Interleukin-1 beta and tumor necrosis factor-alpha inhibit the release of [3H]-noradrenaline from mice isolated atria.

Authors:  S Foucart; C Abadie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.